脂质製剂市场－全球产业规模、份额、趋势、机会及预测（依脂质来源、应用、通路、地区及竞争格局划分，2021-2031年）

全球脂质製剂市场预计将从 2025 年的 40.4 亿美元成长到 2031 年的 67.2 亿美元，复合年增长率为 8.85%。

这些製剂作为重要的药物传递系统，利用脂质辅料溶解疏水性活性药物成分，从而提高其在体内的吸收率。市场成长的主要驱动力是迫切需要提高难溶性候选药物的生物利用度，以及生物製药产业的蓬勃发展——该产业需要可靠的复杂分子载体。根据药物化学及相关技术协会（DCAT）预测，2024年FDA核准的新药中将有32%为生物製药，这项数据表明，该产业越来越依赖脂质奈米颗粒等先进的递送载体来确保疗效。

儘管这些因素推动了强劲的发展势头，但该行业仍面临着与产品技术耐久性相关的一些挑战。可能阻碍市场扩张的一个主要挑战是脂质製剂固有的物理化学不稳定性，这通常需要昂贵的生产过程和严格的储存条件来防止劣化。

市场驱动因素

mRNA疫苗和基因疗法研发管线的快速成长正在从根本上改变市场格局，对先进脂质奈米颗粒（LNP）的需求空前高涨，以确保脆弱的核酸能够顺利递送至细胞内并保持其稳定性。这一趋势迫使药物研发人员优先考虑脂质载体而非传统赋形剂，因为这些先进的转运体对于保护遗传物质免受酵素降解至关重要。根据美国基因与细胞治疗学会于2024年4月发布的《基因、细胞和RNA疗法现状：2024年第一季季数据报告》，全球基因、细胞和RNA治疗方法开发平臺已扩展至4000多种，显示市场对支持这些新一代疗法的专用脂质製剂的需求将持续旺盛。

同时，越来越多的慢性病和肿瘤适应症正在加速脂质体系统的应用，以提高难溶性化疗药物的生物利用度并降低其全身毒性。製造商正利用这些製剂最大限度地提高增强渗透性和滞留效应（PERE），从而增加药物在肿瘤部位的蓄积。大量患者亟需有效的治疗，凸显了这项庞大的需求。根据世界卫生组织（WHO）于2024年2月发布的《全球癌症负担预测》，2022年全球将新增约2,000万例癌症病例。市场对这些压力的反应体现在对生产能力的大规模投资。例如，诺和诺德（Novo Holdings）于2024年以165亿美元收购Catalent的协议，就反映了市场对确保复杂生物製药递送系统生产能力的高度重视。

市场挑战

脂质製剂固有的物理化学不稳定性严重阻碍了全球市场的持续扩张。复杂的递送系统，尤其是脂质奈米颗粒，极易发生氧化、水解和聚集等劣化过程，因此需要高度专业化、资本密集的生产流程和严格的低温运输物流。如果无法持续满足这些严格的稳定性要求，则可能损害产品完整性，导致批次报废和供应链中断，从而造成重大经济损失，直接限制市场扩充性。

生产线的这种脆弱性会带来实际的经济后果，阻碍经济成长。技术稳定性方面的困难往往会导致生产中断和关键治疗药物的大范围供不应求，使企业无法充分满足市场需求。根据美国卫生系统药剂师协会预测，2024年该产业将出现创纪录的323种药品短缺，而这场危机通常是由与复杂无菌注射相关的品质和生产难题引发的。这些可靠性问题迫使製造商将投资转向纠正措施和合规工作，而不是创新，最终减缓了整个产业的商业性发展进程。

市场趋势

将复杂製剂的研发策略性外包给专业的合约研发生产机构 (CDMO) 正逐渐成为主流。这一趋势的驱动力在于製药公司需要在不承担大量内部资本成本的情况下获得专有技术。脂质奈米粒 (LNP) 等脂质基体系需要高度专业化的组装平台，例如衝击射流混合和微流体技术，以确保粒径和包覆效率。因此，创新公司越来越多地与提供全面服务的契约製造合作。正如 CordenPharma 在 2025 年 10 月发表的报导《CDMO 的关键平台投资：产能和药物模式》中所述，该公司于 2025 年 3 月透过其位于 Caponago 的工厂获得 GMP 认证，从而加强了其脂质奈米粒技术。此前，该公司进行了策略性扩建，新增了约 900平方公尺的专业 GMP 生产空间。

同时，人工智慧在脂质製剂开发上的应用正在革新新型辅料的筛检和优化。借助机器学习演算法，研究人员现在可以在电脑上预测数千种脂质结构的稳定性、毒性和转染效率，从而显着减少对传统、费力的试验试验的依赖。这种数据驱动的方法对于设计能够精准靶向特定组织并最大限度降低免疫抗原性反应的可电离脂质至关重要。根据2025年11月发表在《自然·生物技术》杂誌上的一项题为「利用人工智慧设计用于肺部基因治疗的脂质奈米颗粒」的研究，研究人员利用深度学习策略成功评估了160万种脂质结构，并筛选出能够显着提高mRNA有效载荷递送效率的新型候选脂质。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章 全球脂质製剂市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 依脂质来源（天然来源与化学合成）分类
  • 依应用领域（真菌感染疾病、肿瘤、基因治疗、抗病毒疫苗等）
  • 按分销管道（零售药局、医院药局、网路药局）
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章 北美脂质製剂市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

7. 欧洲脂质製剂市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区脂质製剂市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东和非洲脂质製剂市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

10. 南美洲脂质製剂市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球脂质製剂市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• ABITEC Corporation
• BASF
• Gattefosse
• CordenPharma
• Lipoid
• IOI Oleo GmbH
• Croda International
• Evonik Industries
• Ashland
• Merck KGaA

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Lipid Based Formulations Market is projected to increase from USD 4.04 Billion in 2025 to USD 6.72 Billion by 2031, reflecting a CAGR of 8.85%. These formulations serve as essential drug delivery systems, employing lipid excipients to solubilize hydrophobic active pharmaceutical ingredients and improve their absorption within the body. Market growth is chiefly driven by the urgent need to enhance the bioavailability of poorly water-soluble drug candidates and the growing biopharmaceutical sector, which demands reliable carriers for complex molecules. According to the Drug, Chemical & Associated Technologies Association, 32% of novel drugs approved by the FDA in 2024 were biologics, a statistic that highlights the industry's increasing reliance on advanced delivery vehicles like lipid nanoparticles to guarantee therapeutic efficacy.

Despite the robust momentum generated by these drivers, the sector encounters specific obstacles related to the technical durability of these products. A major challenge potentially hindering market expansion is the intrinsic physicochemical instability of lipid formulations, which frequently requires expensive manufacturing procedures and rigorous storage conditions to avoid degradation.

Market Driver

The rapid growth of mRNA vaccine and gene therapy pipelines is fundamentally transforming the market, creating an unparalleled requirement for advanced lipid nanoparticles (LNPs) to ensure the intracellular delivery and stability of delicate nucleic acids. This trend compels pharmaceutical developers to favor lipid-based carriers over conventional excipients, as these sophisticated vehicles are vital for shielding genetic material from enzymatic breakdown. As reported by the American Society of Gene & Cell Therapy in their 'Gene, Cell, & RNA Therapy Landscape: Q1 2024 Quarterly Data Report' in April 2024, the global pipeline has expanded to include over 4,000 gene, cell, and RNA therapies, indicating a lasting demand for specialized lipid formulations to support these next-generation treatments.

Simultaneously, the rising prevalence of chronic diseases and oncology indications is quickening the adoption of liposomal systems aimed at improving the bioavailability of poorly soluble chemotherapeutics and decreasing systemic toxicity. Manufacturers are utilizing these formulations to capitalize on the enhanced permeability and retention effect, thereby increasing drug accumulation at tumor sites. This critical demand is emphasized by the high volume of patients requiring effective care; according to the World Health Organization's 'Global Cancer Burden Estimates' from February 2024, there were approximately 20 million new cancer cases globally in 2022. The market's response to these pressures is evident in major investments in manufacturing capacity, such as Novo Holdings' 2024 agreement to acquire Catalent for $16.5 billion, reflecting the high value placed on securing production capabilities for complex biopharmaceutical delivery systems.

Market Challenge

The inherent physicochemical instability of lipid-based formulations poses a significant obstacle to the continued expansion of the global market. These complex delivery systems, particularly lipid nanoparticles, are susceptible to degradation processes such as oxidation, hydrolysis, and aggregation, which necessitate highly specialized, capital-intensive manufacturing operations and strict cold chain logistics. Failure to consistently maintain these rigorous stability requirements compromises product integrity, resulting in substantial financial losses from wasted batches and supply chain interruptions that directly limit market scalability.

This fragility in the production pipeline has tangible economic impacts that impede growth. The difficulty in ensuring technical robustness often leads to production halts and widespread availability issues for critical therapies, preventing companies from fully satisfying market demand. According to the American Society of Health-System Pharmacists, the industry faced a record high of 323 active drug shortages in 2024, a crisis frequently driven by quality and manufacturing hurdles associated with complex sterile injectables. Such reliability issues force manufacturers to redirect investment toward remediation and compliance rather than innovation, thereby slowing the overall commercial progress of the sector.

Market Trends

Strategic outsourcing of complex formulation development to specialized CDMOs is becoming a dominant trend, driven by the need for pharmaceutical companies to access proprietary technologies without incurring heavy internal capital costs. Because lipid-based systems such as LNPs require highly specialized assembly platforms like impingement jet mixing and microfluidics to ensure precise particle size and encapsulation efficiency, innovators are increasingly partnering with contract manufacturers that offer comprehensive capabilities. As noted by CordenPharma in the article 'CDMO Key Platform Investment in Capacity & Pharma Modalities' in October 2025, the company strengthened its lipid nanoparticle capabilities by obtaining GMP certification for its Caponago facility in March 2025, following a strategic expansion that added approximately 900 square meters of specialized GMP manufacturing space.

Concurrently, the integration of artificial intelligence into lipid formulation development is revolutionizing the screening and optimization of new excipients. By employing machine learning algorithms, researchers can now predict the stability, toxicity, and transfection efficiency of thousands of lipid structures in silico, significantly reducing reliance on traditional, labor-intensive trial-and-error experiments. This data-driven approach is critical for designing ionizable lipids that precisely target specific tissues while minimizing immunogenic responses. According to the study 'Artificial intelligence-guided design of lipid nanoparticles for pulmonary gene therapy' published in Nature Biotechnology in November 2025, researchers successfully utilized a deep-learning strategy to evaluate 1.6 million lipid structures, identifying novel candidates with significantly improved delivery efficiency for mRNA payloads.

Key Market Players

• ABITEC Corporation
• BASF
• Gattefosse
• CordenPharma
• Lipoid
• IOI Oleo GmbH
• Croda International
• Evonik Industries
• Ashland
• Merck KGaA

Report Scope

In this report, the Global Lipid Based Formulations Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Lipid Based Formulations Market, By Source of Lipids

• Natural v/s Chemically Synthesized

Lipid Based Formulations Market, By Application

• Fungal Diseases
• Oncology
• Gene Therapy
• Antiviral Vaccines
• Others

Lipid Based Formulations Market, By Distribution Channel

• Retail Pharmacies
• Hospital Pharmacies
• Online Pharmacies

Lipid Based Formulations Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Lipid Based Formulations Market.

Available Customizations:

Global Lipid Based Formulations Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Lipid Based Formulations Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Source of Lipids (Natural v/s Chemically Synthesized)
  • 5.2.2. By Application (Fungal Diseases, Oncology, Gene Therapy, Antiviral Vaccines, Others)
  • 5.2.3. By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Lipid Based Formulations Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Source of Lipids
  • 6.2.2. By Application
  • 6.2.3. By Distribution Channel
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Lipid Based Formulations Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Source of Lipids
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By Distribution Channel
  • 6.3.2. Canada Lipid Based Formulations Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Source of Lipids
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By Distribution Channel
  • 6.3.3. Mexico Lipid Based Formulations Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Source of Lipids
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By Distribution Channel

7. Europe Lipid Based Formulations Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Source of Lipids
  • 7.2.2. By Application
  • 7.2.3. By Distribution Channel
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Lipid Based Formulations Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Source of Lipids
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By Distribution Channel
  • 7.3.2. France Lipid Based Formulations Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Source of Lipids
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By Distribution Channel
  • 7.3.3. United Kingdom Lipid Based Formulations Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Source of Lipids
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By Distribution Channel
  • 7.3.4. Italy Lipid Based Formulations Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Source of Lipids
      • 7.3.4.2.2. By Application
      • 7.3.4.2.3. By Distribution Channel
  • 7.3.5. Spain Lipid Based Formulations Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Source of Lipids
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By Distribution Channel

8. Asia Pacific Lipid Based Formulations Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Source of Lipids
  • 8.2.2. By Application
  • 8.2.3. By Distribution Channel
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Lipid Based Formulations Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Source of Lipids
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By Distribution Channel
  • 8.3.2. India Lipid Based Formulations Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Source of Lipids
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By Distribution Channel
  • 8.3.3. Japan Lipid Based Formulations Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Source of Lipids
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By Distribution Channel
  • 8.3.4. South Korea Lipid Based Formulations Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Source of Lipids
      • 8.3.4.2.2. By Application
      • 8.3.4.2.3. By Distribution Channel
  • 8.3.5. Australia Lipid Based Formulations Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Source of Lipids
      • 8.3.5.2.2. By Application
      • 8.3.5.2.3. By Distribution Channel

9. Middle East & Africa Lipid Based Formulations Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Source of Lipids
  • 9.2.2. By Application
  • 9.2.3. By Distribution Channel
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Lipid Based Formulations Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Source of Lipids
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By Distribution Channel
  • 9.3.2. UAE Lipid Based Formulations Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Source of Lipids
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By Distribution Channel
  • 9.3.3. South Africa Lipid Based Formulations Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Source of Lipids
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By Distribution Channel

10. South America Lipid Based Formulations Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Source of Lipids
  • 10.2.2. By Application
  • 10.2.3. By Distribution Channel
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Lipid Based Formulations Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Source of Lipids
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By Distribution Channel
  • 10.3.2. Colombia Lipid Based Formulations Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Source of Lipids
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By Distribution Channel
  • 10.3.3. Argentina Lipid Based Formulations Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Source of Lipids
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Lipid Based Formulations Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. ABITEC Corporation
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. BASF
• 15.3. Gattefosse
• 15.4. CordenPharma
• 15.5. Lipoid
• 15.6. IOI Oleo GmbH
• 15.7. Croda International
• 15.8. Evonik Industries
• 15.9. Ashland
• 15.10. Merck KGaA

16. Strategic Recommendations

17. About Us & Disclaimer